» Articles » PMID: 21868618

Improvement in the Renal Prognosis in Nephropathic Cystinosis

Overview
Specialty Nephrology
Date 2011 Aug 27
PMID 21868618
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Nephropathic cystinosis (NC) is an autosomal recessive disorder occurring in one to two per 100,000 newborns. Because of the rarity of NC, long-term outcome data are scarce.

Design, Setting, Participants, & Measurements: 245 NC patients from 18 countries provided data to the ESPN/ERA-EDTA registry. We matched NC patients on renal replacement therapy (RRT) to non-NC children on RRT.

Results: Between 1979 and 2008, mean age at the start of RRT among NC children increased by 0.15 year per calendar year (95% confidence interval, 0.10 to 0.21) from 8.8 to 12.7 years, whereas we did not observe this in non-NC children. Five-year survival after the start of RRT improved in NC patients from 86.1% (before 1990) to 100% (since 2000) as compared with the control population (89.6% and 94.0%). NC patients received a renal allograft more often (relative risk, 1.09; 95% confidence interval, 1.00 to 1.17) as compared with matched RRT children, and 5-year graft survival was better (94.0% versus 84.0%). NC dialysis patients were less often hypertensive than non-NC children matched for age, country, and dialysis modality (42.7% versus 51.7%) and had lower parathyroid hormone levels (median, 56 versus 140 pg/ml). Although height at start of RRT slightly improved during the past decade, children with NC remained significantly shorter than non-NC children at the start of RRT.

Conclusions: We demonstrated improved survival of the renal function as well as better patient and graft survival after the start of RRT in a large European cohort of NC patients over the last two decades.

Citing Articles

Addressing the psychosocial aspects of transition to adult care in patients with cystinosis.

Stabouli S, Sommer A, Kraft S, Schweer K, Bethe D, Bertholet-Thomas A Pediatr Nephrol. 2024; 39(10):2861-2874.

PMID: 38517536 PMC: 11349776. DOI: 10.1007/s00467-024-06345-1.


Extrarenal complications of cystinosis.

Topaloglu R Pediatr Nephrol. 2023; 39(8):2283-2292.

PMID: 38127152 DOI: 10.1007/s00467-023-06225-0.


Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.

Lashilola S, Xu W, Azimpour K, McCarthy M, Carlot S, Game D BMC Nephrol. 2023; 24(1):351.

PMID: 38031005 PMC: 10688492. DOI: 10.1186/s12882-023-03392-y.


Chest configuration in children and adolescents with infantile nephropathic cystinosis compared with other chronic kidney disease entities and its clinical determinants.

Muller S, Kluck R, Jagodzinski C, Brugelmann M, Hohenfellner K, Buscher A Pediatr Nephrol. 2023; 38(12):3989-3999.

PMID: 37415042 PMC: 10584709. DOI: 10.1007/s00467-023-06058-x.


A Policy Call to Address Rare Kidney Disease in Health Care Plans.

Vanholder R, Coppo R, Bos W, Damato E, Fakhouri F, Humphreys A Clin J Am Soc Nephrol. 2023; 18(11):1510-1518.

PMID: 37294578 PMC: 10637461. DOI: 10.2215/CJN.0000000000000220.


References
1.
Wilmer M, Emma F, Levtchenko E . The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol. 2010; 299(5):F905-16. DOI: 10.1152/ajprenal.00318.2010. View

2.
. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(2 Suppl 4th Report):555-76. View

3.
Kuczmarski R, Ogden C, Guo S, Grummer-Strawn L, Flegal K, Mei Z . 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002; (246):1-190. View

4.
Besouw M, Levtchenko E . Growth retardation in children with cystinosis. Minerva Pediatr. 2010; 62(3):307-14. View

5.
Greco M, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F . Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Pediatr Nephrol. 2010; 25(12):2459-67. DOI: 10.1007/s00467-010-1641-8. View